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Abstract
P. multocida is a Gram-negative pathogen responsible for causing diseases in animals of economic
significance to livestock industries throughout the world. Current vaccines include bacterins, which
provide only limited protection against homologous serotypes. Therefore there is a need for more
effective vaccines to control diseases caused by P. multocida. As a step towards developing vaccines
against fowl cholera, a genomics based approach was applied for the identification of novel
immunogens.
Results: Bioinformatics analysis of the P. multocida genome predicted 129 proteins as secreted,
located in the outer membrane, or lipoproteins. 105 of the genes encoding these proteins were
cloned and recombinant protein expressed in Escherichia coli. Polyclonal serum from P. multocida-
infected chickens reacted with a subset of these proteins.
Conclusion: These data show the range of bacterial immunogens recognized by the chicken
immune system, including 6 novel immunoreactive proteins.
Background
Pasteurella multocida is a Gram-negative bacterial patho-
gen which is the causative agent of a range of diseases in
animals, including fowl cholera in avian species, hemor-
rhagic septicemia in ungulates, shipping fever and pneu-
monia in cattle, atrophic rhinitis in swine, and snuffles in
rabbits [1-3]. The bacterium also causes infection in
humans, primarily through dog and cat bites. Fowl chol-
era, which is generally caused by serotypes A:1, A:3 or A:4
[4], is a severe systemic disease which occurs in domestic
poultry and wild birds and results in significant economic
losses to poultry industries worldwide. Current vaccines
against fowl cholera include bacterins [5], which provide
only limited protection against homologous serotypes
and live attenuated strains, which have been observed to
revert to virulence [6]. Therefore, there is a need for more
effective vaccines to control diseases caused by P. multoc-
ida.
The surface of Gram-negative bacteria is critical for inter-
action of the bacterium with the host cell environment as
it mediates nutrient uptake, secretion of toxins and other
products and is involved in avoidance of the host immune
system [7]. Furthermore, it is the bacterial surface mole-
cules that are the targets for host immunity. Indeed, bac-
terial surface proteins have been shown to be important
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models [8,9]. Recently, the P. multocida PlpB protein was
identified as a cross-protective antigen [10,11] and this
protein is located in the P. multocida outer membrane
[12]. Outer membrane proteins also promote adherence
to host cell surfaces and are therefore likely to be involved
in P. multocida virulence [13].
In an effort to identify novel immunogens to which chick-
ens respond during natural infection, and as a first step
towards developing protective recombinant vaccines
against fowl cholera, a detailed antigen profiling analysis
was undertaken. The effectiveness of this approach, which
has been termed 'reverse vaccinology' or 'reverse immu-
nology', has been reported by several authors with Plasmo-
dium falciparum [14], Streptococcus pneumoniae [15],
Treponema pallidum [16], Neisseria meningitidis [17], and
Chlamydia pneumoniae [18].
Results and discussion
We utilised a range of bioinformatics analyses of the
annotated P. multocida Pm70 genome sequence and previ-
ously published experimental data [12] to select genes
likely to have vaccine potential. The central premise of
this work was that protective antigens are likely to be sur-
face exposed or secreted by the bacteria and therefore
accessible to the host immune response. We used PSORTB
[19] and ProteomeAnalyst [20] to predict all outer mem-
brane and secreted proteins and LipoP [21] to predict all
lipoproteins. We included all lipoproteins as a large
number of lipoproteins was observed in the proteomics
analysis of the P. multocida outer membrane [12] and we
believe that precise sub-cellular prediction of lipoprotein
location (inner or outer membrane) is presently unrelia-
ble. These bioinformatics analyses identified a combined
list of 129 proteins (Figure 1, see Additional file 1). The
prediction programs PSORTB and ProteomeAnalyst can
be used to predict protein localisation in Gram-negative
organisms, while LipoP specifically predicts Gram-nega-
tive lipoproteins. PSORTB and ProteomeAnalyst use dif-
ferent methods for prediction of localisations. PSORTB
uses primary sequence analysis algorithms and gives a
high precision, but low sensitivity, prediction. Proteome
analyst on the other hand utilises analysis of text annota-
tions for the closest homologue of any given query
sequence and is medium-high precision and sensitivity; it
thus makes a higher number of predictions. These analy-
ses were complemented by the previously published pro-
teomic analysis of the P. multocida outer membrane [12]
which identified three proteins (PM0612, PM1357 and
PM1746) not predicted by bioinformatics.
The large number of candidate genes necessitated the
adoption of a high-throughput cloning strategy, which
utilised by the Gateway™trogen Inc., Carlsbad, CA) clon-
ing and expression system to clone PCR-amplified P. mul-
tocida ORFs. An attempt was made to clone all 129 ORFs;
however, only 105 were successfully cloned and expressed
in E. coli. Each of the recombinant expression clones was
assessed for levels of protein expression and solubility.
Because of the large inventory of proteins that were
required to be expressed and purified in a time and cost
effective way, protein expression was analysed using a
novel inclusion body assay developed on a TECAN liquid
handling robot.
To evaluate the range of P. multocida proteins recognised
by the chicken antibody response, serum samples from
chickens that had been repeatedly infected with P. multoc-
ida and then treated with antibiotics were tested for reac-
tivity against 105 recombinant proteins by Western blot.
Pooled serum samples from P. multocida infected chickens
(8 from X-73, 3 from VP161 – a highly virulent A:1 strain
[22]) and four serum samples from control chickens were
reacted in immunoblot assays with comparable amounts
(3 μg/lane) of recombinant proteins. The immune
chicken sera generated during P. multocida strain X-73 or
VP161 infection recognised a total of 12 (Table 1) recom-
binant proteins, ten of which were not recognised by
naive sera. To our knowledge, six of these antigens have
not been previously identified as capable of eliciting
immune responses from chickens, demonstrating the util-
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noreactive bacterial antigens (Figure 2). Although
immunological reactivity to unique antigens alone does
not necessarily indicate a role in protective immunity
against pasteurellosis, these novel antigens constitute
prime candidates as potential vaccine targets for pasteurel-
losis, and warrant inclusion in studies to elucidate their
potential role in pathogensis. The results have important
implications in understanding avian immune responses
to P. multocida and in elucidating putative elements of a
protective immune response.
One drawback of this immunogen discovery assay is that
it is limited to protein coding regions that can be
expressed in E. coli. In addition, antibodies that recognise
only conformational epitopes that are denatured in SDS-
PAGE will not be detected. Furthermore, a lack of anti-
body recognition to recombinant proteins may be the
result of a poor immune response to these antigens during
infection or alternatively, a reflection of differential
expression of antigens by the VP161 and X-73 strains
within the host. Four of the six novel proteins (PM0442,
PM0659, PM0979, PM1614) were identified as putative
lipoproteins characterised by a cysteine residue after a sig-
nal peptide. PM1993 was predicted to contain a signal
peptide processed by signal peptidase 1. These results do
not preclude the existence of additional immunogens
present in other serotypes.
Conclusion
In summary, this work represents a systematic and com-
prehensive approach for the characterisation of the
immune response associated with pasteurellosis by tar-
geted computational screening of genomic sequences
with predictive antigenic properties, followed by an auto-
mated high throughput expression and purification strat-
egy using a robotic platform. It has resulted in the
identification of 12 immunogenic determinants which are
clearly expressed in vivo during infection, six of which
were unique to this study, and thus constitute candidates
for the development of a protective vaccine against fowl
cholera. We are currently evaluating the protective effects
of these P. multocida proteins against bacterial challenge in
chickens.
Methods
Cloning of P.multocida genes
The Pm70 genome sequence was used when designing
primers for X-73, which is virulent for chickens, while
Pm70 does not cause disease in chickens. PCR primers
were designed to amplify the gene region encoding the
mature length protein (excluding the signal sequence)
except where a signal sequence could not be predicted and
then the primers were designed to encompass the entire
gene. All 5' PCR primers included a 5'-CACC tail to facili-
tate directional topoisomerase cloning and where the
primers had been designed to amplify only the mature
length portion (without the signal sequence) the 5'-CAC-
CATG tail was added so as to include a start codon. As the
genes were to be expressed in-frame with either a C-termi-
nal or an N-terminal tag the native stop codon was not
included in the reverse primers. All PCR products were
amplified from P. multocida strain X-73 (serotype A:1),
which is highly virulent for chickens, and cloned into the
Gateway entry vector pENTR/SD/D-TOPO® (Invitrogen
Inc. Carlsbad, CA). After the cloned genes were verified by
sequencing and restriction digestion analysis, they were
transferred by recombination (LR Clonase kit – Invitrogen
Inc., Carlsbad, CA) from the entry clone to the Invitrogen
destination vectors pBAD-DEST49™, pDEST-17™ and a
Gateway adapted expression vector containing a NusA
solubility tag, pLIC-Nus [23].
Protein expression
Briefly, 1 ml of each culture (Overnight Express™, Nova-
gen, Madison, WI) was chemically lysed with PopCulture
(Novagen, Madison, WI), and Lysonase™ (Novagen, Mad-
ison, WI). The cell lysate was then added to a 96-well filter
Table 1: P. multocida antigens recognised by immune chicken sera. +, reaction; -, no reaction.
Antigen Database similarity (accession no.) X-73 sera VP161 sera Control sera
PM0388 Outer membrane protein from P. multocida (AAK02472) + + -
PM0442 Hypothetical protein + + -
PM0554 Lipoprotein from P. multocida (AAK02638) - + -
PM0659 Hypothetical protein + + -
PM0786 OmpA from P. multocida (AAT57679) + + +
PM0966 Omp16 from P. multocida (CAB75338) + + +
PM0979 Hypothetical protein + + -
PM1614 Outer membrane protein from Haemophilus (AAX87732) + + -
PM1730 PlpB from P. multocida (AAK03814) - + -
PM1979 SurA protein from Mannheimia (AAU38450) + + -
PM1992 Oma87 from P. multocida (CAD20126) + + -
PM1993 Outer membrane protein from P. multocida serotype D (CAA52400) + + -Page 3 of 5
(page number not for citation purposes)
Microbial Cell Factories 2007, 6:3 http://www.microbialcellfactories.com/content/6/1/3plate (AcroPrep™, EastHills, NY) and the solution was
drawn through under vacuum. The inclusion bodies were
retained while soluble proteins passed through the filter.
The retained inclusion bodies were washed once with Tri-
ton X-100 to remove any remaining soluble proteins, fol-
lowed by two washes with phosphate buffer. The washed
proteins were then denatured by the addition of 200 μl of
8 M urea to each corresponding well, incubated for 2 hr at
room temperature and collected under vacuum. Both sol-
uble and insoluble fractions were then analysed by SDS-
PAGE to assess the solubility of each protein.
Immunoblotting
The membranes were incubated with sera (diluted 1:500)
from either infected or uninfected birds as the primary
antibody and then with a peroxidase-conjugated anti-
chicken antibody (diluted 1:1000) as the secondary anti-
body (Chemicon International Inc., Temecula, CA). 4-
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Western immunoblot demonstrating recognition of six novel P. multocida antigens by po led sera from experimentally inf c d chicke sFigure 2
Western immunoblot demonstrating recognition of six novel 
P. multocida antigens by pooled sera from experimentally 
infected chickens. Sizes of markers in kilodaltons are indi-
cated on the left. Lanes: 1, protein molecular standards (kDa) 
(SeeBlue Plus2 Prestained Sandard, Novagen); 2 and 9 are 
blank; 3, PM0442 (pLIC-Nus); 4, PM0979 (pDEST-17); 5, 
PM0659 (pDEST-17); 6, PM1993 (pDEST-17); 7, PM1614 
(pLIC-Nus); 8, PM1979 (pLIC-Nus); 10, P. multocida X73 
whole cell lysate. All the soluble fusion proteins cloned with 
a NusA tag were cleaved and detected after incubation with 
Tev protease at room temperature for 2 h. The top arrows 
in the corresponding lanes show the expected size of the 
fusion proteins and the bottom arrows mark the recom-
binant proteins without the NusA tag. Lanes with single 
arrows correspond to the recombinant proteins expressed 
in the absence of a NusA tag.
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